Carregant...
Therapy with JAK2 inhibitors for Myeloproliferative Neoplasms
The development of JAK2 inhibitors followed the discovery of activating mutation of JAK2 (JAK2V617F) in patients with classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs). It is now known that mutations activating the JAK-STAT pathway are ubiquitous in Ph-negative MPNs, and...
Guardat en:
| Publicat a: | Hematol Oncol Clin North Am |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406395/ https://ncbi.nlm.nih.gov/pubmed/23009939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2012.07.008 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|